DK1937276T3 - Forbedret testosterongel og fremgangsmåde til anvendelse deraf - Google Patents

Forbedret testosterongel og fremgangsmåde til anvendelse deraf

Info

Publication number
DK1937276T3
DK1937276T3 DK06836341.5T DK06836341T DK1937276T3 DK 1937276 T3 DK1937276 T3 DK 1937276T3 DK 06836341 T DK06836341 T DK 06836341T DK 1937276 T3 DK1937276 T3 DK 1937276T3
Authority
DK
Denmark
Prior art keywords
testosterongel
procedure
improved
improved testosterongel
Prior art date
Application number
DK06836341.5T
Other languages
English (en)
Inventor
Ramana Malladi
Jodi Miller
Original Assignee
Besins Healthcare Luxembourg
Unimed Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37943593&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1937276(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Besins Healthcare Luxembourg, Unimed Pharmaceuticals Llc filed Critical Besins Healthcare Luxembourg
Application granted granted Critical
Publication of DK1937276T3 publication Critical patent/DK1937276T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
DK06836341.5T 2005-10-12 2006-10-12 Forbedret testosterongel og fremgangsmåde til anvendelse deraf DK1937276T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72527605P 2005-10-12 2005-10-12
PCT/US2006/040481 WO2007044976A2 (en) 2005-10-12 2006-10-12 Improved testosterone gel and method of use

Publications (1)

Publication Number Publication Date
DK1937276T3 true DK1937276T3 (da) 2013-02-11

Family

ID=37943593

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06836341.5T DK1937276T3 (da) 2005-10-12 2006-10-12 Forbedret testosterongel og fremgangsmåde til anvendelse deraf
DK11181638.5T DK2450041T3 (da) 2005-10-12 2006-10-12 Forbedret testosterongel til anvendelse i behandlingen af hypogonadisme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11181638.5T DK2450041T3 (da) 2005-10-12 2006-10-12 Forbedret testosterongel til anvendelse i behandlingen af hypogonadisme

Country Status (30)

Country Link
US (11) US20070237822A1 (da)
EP (3) EP3456329A1 (da)
JP (2) JP5584415B2 (da)
KR (1) KR101342357B1 (da)
CN (1) CN101287470B (da)
AU (1) AU2006299833B2 (da)
BR (1) BRPI0617294B8 (da)
CA (1) CA2624788C (da)
CY (1) CY1120904T1 (da)
DK (2) DK1937276T3 (da)
EA (1) EA012754B1 (da)
EC (1) ECSP088363A (da)
ES (2) ES2693745T3 (da)
GE (1) GEP20125432B (da)
HK (1) HK1117417A1 (da)
HR (1) HRP20130071T1 (da)
IL (1) IL190522A (da)
LT (1) LT2450041T (da)
MA (1) MA29941B1 (da)
NO (2) NO346660B1 (da)
NZ (1) NZ567056A (da)
PL (2) PL1937276T3 (da)
PT (2) PT2450041T (da)
RS (1) RS52671B (da)
SI (2) SI1937276T1 (da)
TN (1) TNSN08167A1 (da)
TR (1) TR201815853T4 (da)
UA (1) UA87627C2 (da)
WO (1) WO2007044976A2 (da)
ZA (1) ZA200803087B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
BR0308584A (pt) * 2002-03-15 2005-02-22 Unimed Pharmaceuticals Inc Composição farmacêutica androgênica e método para tratamento de depressão
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
SI1937276T1 (sl) 2005-10-12 2013-04-30 Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road Izboljšani testosteronski gel in postopek uporabe
MX2009008995A (es) * 2007-03-23 2009-09-03 Unimed Pharmaceuticals Llc Composiciones y metodos para tratar hipogonadismo pediatrico.
DK2219603T3 (da) * 2007-11-02 2014-09-01 Acrux Dds Pty Ltd Transdermalt afgivelsessystem
US8962649B2 (en) * 2009-04-01 2015-02-24 iNova Pharmaceuticals (Australia) Pty Limited Multidose package, course and method of treatment for delivering predetermined multiple doses of a pharmaceutical
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US9987213B2 (en) * 2012-06-13 2018-06-05 Edward Dunne Corboy, JR. Topical dihydrotestosterone (DHT) for promoting hair growth—containing formulations
US20140058339A1 (en) * 2012-08-22 2014-02-27 Mark L. Baum Method and apparatus for self-dosing and self-administering pharmaceutical compositions
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
JP6338658B2 (ja) * 2013-10-07 2018-06-06 アンタレス・ファーマ・インコーポレーテッド テストステロンの針補助ジェット注射を通じたヘマトクリット調節
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
WO2015128876A2 (en) * 2014-02-25 2015-09-03 Intas Pharmaceuticals Limited Stable transdermal testosterone gel
US20170014417A1 (en) 2015-07-14 2017-01-19 Lipp Life Sciences Llc Pharmaceutical administration system for the transdermal application of vardenafil
JP6444956B2 (ja) * 2015-09-30 2018-12-26 富士フイルム株式会社 経皮吸収用組成物
JP6838952B2 (ja) * 2016-12-07 2021-03-03 川崎重工業株式会社 ロボット及びロボットに使用される袋体

Family Cites Families (295)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2155658A (en) 1936-01-08 1939-04-25 Chemische Forschungs Gmbh Surgical and medical preparations
US2232508A (en) 1938-10-21 1941-02-18 Lionel Corp Accessory control circuits for toy electric railroads and apparatus therefor
NL109113C (da) 1957-03-27
US3121042A (en) 1959-05-04 1964-02-11 Ercoli Alberto Oral compositions containing 3-enolethers of methyltestosterone
GB916778A (en) 1959-10-15 1963-01-30 Vismara Francesco Spa Oral compositions containing 3-substituted 17-ª--methyl testosterones
GB941634A (en) 1960-11-16 1963-11-13 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
US3218283A (en) 1962-07-26 1965-11-16 Monsanto Co Novel solutions of poly-(acrylic anhydride) and poly-(methacrylic anhydride) polymers
US3164520A (en) 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
GB1158283A (en) 1965-10-21 1969-07-16 Foster Milburn Company Composition to be Applied to Skin and Process for Preparing Same.
US3888995A (en) 1968-07-19 1975-06-10 Syntex Corp Fatty alcohol-propylene glycol vehicle
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3913789A (en) 1974-02-13 1975-10-21 United States Banknote Corp Fluid container of the flexible wall capsule type
US4009254A (en) 1974-05-06 1977-02-22 Colgate-Palmolive Company Topical compositions
US3939111A (en) 1974-07-01 1976-02-17 The B. F. Goodrich Company Stable polyurethane solutions
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4197316A (en) 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
NL7510104A (nl) 1975-08-27 1977-03-01 Akzo Nv Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
US4078060A (en) 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
CH625702A5 (da) 1977-01-18 1981-10-15 Delalande Sa
DE2747531A1 (de) 1977-10-22 1979-04-26 Basf Ag Substituierte 3-aminopyrazole
US4954487A (en) 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4299826A (en) 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
CA1165240A (en) 1980-07-09 1984-04-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4346709A (en) 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
US4442094A (en) 1980-12-23 1984-04-10 Merck & Co., Inc. (3-Aralkylamino-2-or-propoxy)heterocyclic compounds
US4440777A (en) 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4447562A (en) 1981-07-15 1984-05-08 Ivani Edward J Amino-polysaccharides and copolymers thereof for contact lenses and ophthalmic compositions
FR2515041A1 (fr) 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires
FR2518879A1 (fr) 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
FR2519252A1 (fr) 1982-01-07 1983-07-08 Besins Jean Medicament a base de dihydrotestosterone pour le traitement des deficits des secretions androgeniques testiculaires
US4496556A (en) 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
DE3315654A1 (de) 1983-04-29 1984-10-31 Bosch Gmbh Robert Polarographischer messfuehler fuer die bestimmung des sauerstoff-gehaltes in gasen
NL8301550A (nl) 1983-05-03 1984-12-03 Gist Brocades Nv Imidazolethanol esters.
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4631188A (en) 1983-08-31 1986-12-23 S.K.Y. Polymers, Ltd. (Kingston Technologies) Injectable physiologically-acceptable polymeric composition
DE3333240A1 (de) 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4690775A (en) 1983-09-30 1987-09-01 Research Corporation Emulsion-based gel and process for preparing same
US4615697A (en) 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
FR2558373B1 (fr) 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
GB8508404D0 (en) 1985-03-30 1985-05-09 Baylor College Medicine Therapeutic compositions
CA1248450A (en) 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
GB8416234D0 (en) 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4704282A (en) 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4791099A (en) 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
GB2167408B (en) 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
EP0189861A3 (en) 1985-01-26 1988-02-17 Showa Denko Kabushiki Kaisha Percutaneous absorption accelerator for ionic water-soluble medicine
EP0196769B1 (en) 1985-02-25 1992-07-08 Rutgers, The State University of New Jersey A novel transdermal pharmaceutical absorption dosage unit
US4663157A (en) 1985-02-28 1987-05-05 The Proctor & Gamble Company Sunscreen compositions
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4994265A (en) 1985-09-06 1991-02-19 Aloe Scientific Labs Shaving composition
US4683242A (en) 1985-10-28 1987-07-28 A. H. Robins Company, Incorporated Transdermal treatment for pain and inflammation with 2-amino-3-aroylbenzeneacetic acids, salts and esters
EP0222385B1 (en) 1985-11-13 1993-02-03 Research Development Corporation of Japan Sex hormones for the treatment of immunodeficiency diseases
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
DE3690626C2 (de) 1985-12-04 1997-05-15 Dean Hsieh Arzneimittel, enthaltend neben einer wirksamen Arzneistoffmenge ein Lacton oder cyclisches Keton
US4699779A (en) 1986-02-18 1987-10-13 Victor Palinczar Waterproof sunscreen compositions
US4820724A (en) 1986-03-31 1989-04-11 University Of Southern California Dual phase solvent carrier system
US4780320A (en) 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4946870A (en) 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
US4863911A (en) 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
MY102980A (en) 1986-10-31 1993-03-31 Pfizer Transdermal flux enhancing compositions
US4863970A (en) 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4861764A (en) 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US5326790A (en) 1986-11-19 1994-07-05 Dermatologic Research Corporation Administration of skin medications by use of dicarboxylic acids and derivatives
US4981696A (en) 1986-12-22 1991-01-01 E. I. Du Pont De Nemours And Company Polylactide compositions
AU601528B2 (en) 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
US4906169A (en) 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
BE1000381A4 (fr) 1987-03-13 1988-11-16 Pharlyse Sa Preparation pharmaceutique a base d'indometacine.
US4855305A (en) 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
JPS6479103A (en) 1987-06-09 1989-03-24 Lion Corp External preparation
US5013553A (en) 1987-06-30 1991-05-07 Vipont Pharmaceutical, Inc. Drug delivery devices
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US4920203A (en) 1987-12-17 1990-04-24 Allied-Signal Inc. Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US5719197A (en) 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5446070A (en) 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
IE62871B1 (en) 1988-03-08 1995-03-08 Warner Lambert Co Compositions with enhanced penetration
US5231087A (en) 1988-03-16 1993-07-27 Cellegy Pharmaceuticals, Inc. Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids
US5641504A (en) 1988-06-09 1997-06-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolinoleate
CA2000401C (en) 1988-10-11 1996-05-28 Masato Azuma Percutaneous pharmaceutical preparation
EP0370220B1 (de) 1988-10-27 1996-01-10 Schering Aktiengesellschaft Mittel zur transdermalen Applikation enthaltend Gestoden
DE3836862A1 (de) 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5332577A (en) 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
CA2011423A1 (en) 1989-03-07 1990-09-07 Peter M. Taylor Pharmaceutical compositions useful as drug delivery vehicles and/or as wound dressings
IE62715B1 (en) 1989-03-10 1995-02-22 Endorecherche Inc Combination therapy for treatment of estrogen sensitive diseases
US4917882A (en) 1989-03-16 1990-04-17 Amway Corporation Gel-type sunscreen composition
US5053227A (en) 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5788983A (en) 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
DE69010076T2 (de) 1989-05-25 1994-12-08 Takeda Chemical Industries Ltd Transdermales therapeutisches Mittel.
US5059603A (en) 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
DE69034035T2 (de) 1989-07-07 2004-01-22 Endorecherche Inc., Ste-Foy Methode zur behandlung androgenbedingter krankheiten
US5232703A (en) 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
US5116828A (en) 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5324521A (en) 1989-12-18 1994-06-28 Dermamed Systems for transdermal administration of medicaments
JP2893803B2 (ja) 1990-02-27 1999-05-24 日本電気株式会社 プラズマディスプレイの駆動方法
ATE151977T1 (de) 1990-06-01 1997-05-15 Population Council Inc Therapeutisch wirksame, örtliche anwendung von st1435
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
US5202125A (en) 1990-12-10 1993-04-13 Theratech, Inc. Method and systems for administering nitroglycerin transdermally at enhanced transdermal fluxes
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
EP0491076A1 (en) 1990-12-19 1992-06-24 Theratech, Inc. Penetration enhancement with multi-component system of N-aliphatic pyrrolidones with lower alcohols
JPH04261119A (ja) 1991-02-13 1992-09-17 Lintec Corp 経皮吸収型貼付剤
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5211952A (en) 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
TW218849B (da) 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5208013A (en) 1991-06-03 1993-05-04 Olympus International, Inc. Composition for skin care and protection
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
US5238933A (en) 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
JP3202777B2 (ja) 1992-01-24 2001-08-27 リンテック株式会社 経皮吸収促進剤及びテープ製剤
US5629019A (en) 1992-02-27 1997-05-13 Alza Corporation Formulations with hydrophobic permeation enhancers
TW224048B (da) 1992-03-30 1994-05-21 Hoechst Roussel Pharma
JP2960832B2 (ja) 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
US5607691A (en) 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5446025A (en) 1992-06-12 1995-08-29 Abbott Laboratories Formulations and method of the percutaneous administration of leuprolide
EP0644764B1 (en) 1992-06-19 2000-05-17 The Regents of the University of California Lipids for epidermal moisturization and repair of barrier function
DE4223004A1 (de) 1992-07-13 1994-01-20 Liedtke Pharmed Gmbh Einzeldosierte halbfeste topische Arzneiform zur Transdermaltherapie
US5932227A (en) 1992-07-23 1999-08-03 Hisamitsu Pharmaceutical Co., Inc. Percutaneously administrable base composition and drug composition prepared therefrom
JP3276406B2 (ja) 1992-07-24 2002-04-22 富士通株式会社 プラズマディスプレイの駆動方法
EP0581587A3 (en) 1992-07-31 1995-05-17 Tanabe Seiyaku Co Base material for transdermal administration.
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
US5883115A (en) 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
WO1994013257A1 (en) 1992-12-16 1994-06-23 Creative Products Resource Associates, Ltd. Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
WO1994016709A2 (en) 1993-01-19 1994-08-04 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5881926A (en) 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
US6010691A (en) 1993-03-19 2000-01-04 The Regents Of The University Of California Methods for enhancing permeation of a topically administered physiologically active substance
JP3204510B2 (ja) 1993-04-05 2001-09-04 コンペティティブ テクノロジーズ，インク． ***不全の診断および治療
EP0698393B1 (en) 1993-05-19 2002-07-03 Hisamitsu Pharmaceutical Co., Inc. 3-l-MENTHOXY-PROPANE-1, 2-DIOL AS SOLUBILIZING AGENT AND EXTERNAL PREPARATION CONTAINING THE SAME
US5648350A (en) 1993-05-25 1997-07-15 Laboratoires Besins Iscovesco Dihydrotestosterone for use in androgenotherapy
US5460820B1 (en) 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
WO1995017896A1 (fr) 1993-12-27 1995-07-06 Akzo Nobel N.V. Preparation pour absorption par voie percutanee
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
CN1106259A (zh) 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂
FR2718372B1 (fr) 1994-04-08 1996-06-28 Sofab Dispensateur de produits fluides.
ATE189121T1 (de) 1994-04-22 2000-02-15 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
JP4102901B2 (ja) 1994-09-14 2008-06-18 スリーエム カンパニー 経皮薬剤導入用マトリックス
AU695170B2 (en) 1994-12-21 1998-08-06 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
US5807568A (en) 1994-12-27 1998-09-15 Mcneil-Ppc, Inc. Enhanced delivery of topical compositions containing flurbiprofen
US6024974A (en) 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
AT408067B (de) 1995-03-17 2001-08-27 Gebro Pharma Gmbh Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
US5844103A (en) 1995-03-24 1998-12-01 Lever Brothers Company, Division Of Conopco, Inc. Anionic glycasuccinamide sufactants and a process for their manufacture
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
FR2732223B1 (fr) 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
DE19517145C2 (de) 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
PL181582B1 (pl) 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Plaster na skóre do zapobiegania owulacji u kobiety oraz plaster na skóre do przeprowadzania hormonalnej terapii substytucyjnej PL PL PL PL PL PL PL PL
US5785991A (en) 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
GB9512670D0 (en) 1995-06-21 1995-08-23 Sod Conseils Rech Applic Camptothecin analogues
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5902603A (en) 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6036977A (en) 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
US5849729A (en) 1995-12-26 1998-12-15 Hershey Foods Corporation Use of hydrolyzed cocoa butter for percutaneous absorption
US5643587A (en) 1996-02-15 1997-07-01 Avon Products, Inc. Composition and method for under-eye skin lightening
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5898038A (en) 1996-03-19 1999-04-27 Board Of Regents, The University Of Texas System Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
DE19619045C1 (de) 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
IT1283102B1 (it) 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
US5730987A (en) 1996-06-10 1998-03-24 Omar; Lotfy Ismail Medication for impotence containing lyophilized roe and a powdered extract of Ginkgo biloba
US5708038A (en) 1996-06-13 1998-01-13 Univera Pharmaceuticals, Inc. Method of using aloe vera as a biological vehicle
US6007837A (en) 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US6139873A (en) 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5770226A (en) 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
RU2122396C1 (ru) 1996-07-12 1998-11-27 Валентина Александровна Андрюшина Биологически-активная добавка в косметические изделия
US6228852B1 (en) 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5837289A (en) 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
US6225299B1 (en) 1996-09-16 2001-05-01 Jenapharm Gmbh & Co. Kg Hormonal agent for skin treatment
US5760096A (en) 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
KR20000035801A (ko) 1996-10-30 2000-06-26 에버트 챨스 디 침투증강제로써라틱산지방산에스테르염
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6019988A (en) 1996-11-18 2000-02-01 Bristol-Myers Squibb Company Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
US5855920A (en) 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US5807957A (en) 1996-12-23 1998-09-15 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
US5908619A (en) 1997-01-09 1999-06-01 Minnesota Mining And Manufacturing Company Hydroalcoholic compositions thickened using surfactant/polymer complexes
US6019997A (en) 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
GB9700878D0 (en) 1997-01-17 1997-03-05 Scherer Ltd R P Dosage forms and method for ameliorating male erectile dysfunction
US20010023261A1 (en) 1997-01-27 2001-09-20 Lg Chemical Limited. Novel composition for the transdermal administration of drugs
DE69829961T2 (de) 1997-02-28 2006-02-23 Minnesota Mining And Mfg. Co., Saint Paul Transdermale vorrichtung zur verabreichungvon von testosteron
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US5968919A (en) 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6156753A (en) 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
US20020013304A1 (en) 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
CA2306837C (en) 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6127363A (en) 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
JP4139860B2 (ja) * 1997-11-10 2008-08-27 ストラカン インターナショナル リミティッド 浸透増強および刺激減少システム
WO1999026630A1 (en) 1997-11-24 1999-06-03 University Of Florida Research Foundation, Incorporated Testosterone inhibitors and use for the protection of neurons
US6267984B1 (en) 1997-12-22 2001-07-31 Alza Corporation Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
EP1043020A1 (en) 1997-12-25 2000-10-11 Daiichi Pharmaceutical Co., Ltd. Medicinal composition for percutaneous administration
US5935949A (en) 1998-03-20 1999-08-10 Trustees Of Dartmouth College Use of androgen therapy in fibromyalgia and chronic fatigue syndrome
AU3567699A (en) 1998-04-17 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
FR2777784B1 (fr) 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
US6124461A (en) 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US5847128A (en) 1998-05-29 1998-12-08 Virginia Commonwealth University Water soluble derivatives of cannabinoids
US6277884B1 (en) 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
US6087368A (en) 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE19825856A1 (de) 1998-06-10 1999-12-16 Labtec Gmbh Topische Arzneimittelzubereitung
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
AU4696499A (en) 1998-06-19 2000-01-05 Genetronics, Inc. Electrically assisted transdermal method and apparatus for the treatment of erectile dysfunction
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US5880117A (en) 1998-07-13 1999-03-09 Arnold; Patrick Use of 4-androstenediol to increase testosterone levels in humans
US6207694B1 (en) 1998-07-27 2001-03-27 Howard Murad Pharmaceutical compositions and methods for managing scalp conditions
US6284234B1 (en) 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
US6077841A (en) 1998-09-04 2000-06-20 Janssen Pharmaceutica, N.V. 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
EP1005831A3 (en) 1998-12-04 2001-05-30 Eisai Co., Ltd. A method for measurement of a penile diameter
US6224573B1 (en) 1999-01-15 2001-05-01 Nexmed Holdings, Inc. Medicament dispenser
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
JP2000212080A (ja) 1999-01-26 2000-08-02 Hiroshi Azuma ***機能不全改善剤
DE19903087A1 (de) 1999-01-27 2000-08-10 Forssmann Wolf Georg Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6087362A (en) 1999-03-16 2000-07-11 Pentech Pharmaceuticals, Inc. Apomorphine and sildenafil composition
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6187750B1 (en) 1999-08-25 2001-02-13 Everyoung Technologies, Inc. Method of hormone treatment for patients with symptoms consistent with multiple sclerosis
US6075028A (en) 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
US6980566B2 (en) 2000-03-10 2005-12-27 Lightwaves Systems, Inc. Method for routing data packets using an IP address based in GEO position
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
AU3104301A (en) 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
JP3596464B2 (ja) * 2000-02-10 2004-12-02 セイコーエプソン株式会社 計時装置および計時装置の制御方法
DE10015783C2 (de) 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
CZ20023637A3 (cs) 2000-04-07 2003-02-12 Tap Pharmaceutical Products, Inc. Deriváty apomorfinu a způsoby jejich použití
PL360992A1 (en) 2000-08-30 2004-09-20 Unimed Pharmaceuticals,Inc. Method of increasing testosterone and related steroid concentrations in women
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
EP1315502B1 (en) * 2000-08-30 2010-03-17 Unimed Pharmaceuticals, LLC Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
JP5039252B2 (ja) 2000-08-31 2012-10-03 ユニメッド ファーマシューティカルズ，リミティド ライアビリティ カンパニー 性機能低下を治療するための医薬組成物及び方法
FR2814074B1 (fr) 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
SI1347764T1 (sl) 2000-12-22 2007-06-30 August Wolff Gmbh & Co Kg Arzenmittel Dr Gelni sestavek na alkoholni osnovi za zdravljenje hipogonadizma s trans-skrotalno aplikacijo
JP2002212105A (ja) 2001-01-22 2002-07-31 Lion Corp 水性皮膚外用剤組成物
EP1390024A4 (en) 2001-05-11 2010-02-17 Merrion Res Iii Ltd ISOSTEARIC ACID SALTS AS PERMEATION IMPROVERS
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
AU2002340120A1 (en) 2001-10-04 2003-04-14 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
ES2330188T3 (es) 2001-12-07 2009-12-07 Besins Manufacturing Belgium Composicion farmaceutica en forma de gel o de solucion a base de dihidrotestoterona, su procedimiento de preparacion y sus utilizaciones.
US20060088579A1 (en) 2002-02-07 2006-04-27 Shastri Venkatram P Transdermal drug delivery systems
BR0308584A (pt) 2002-03-15 2005-02-22 Unimed Pharmaceuticals Inc Composição farmacêutica androgênica e método para tratamento de depressão
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
CN1470239A (zh) 2002-07-28 2004-01-28 王怀秀 睾酮经皮缓释制剂
FR2848112B1 (fr) 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US7968532B2 (en) 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
RU2275930C2 (ru) 2004-04-26 2006-05-10 ООО "РусГен" Композиция для коррекции возрастных изменений эндокринной системы человека (варианты) и способ получения фармацевтической формы на основе такой композиции
US20070190124A1 (en) 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US20070189977A1 (en) 2004-06-07 2007-08-16 Jie Zhang Spray-on formulations and methods for dermal delivery of drugs
US20070196453A1 (en) 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US20070196323A1 (en) 2004-06-07 2007-08-23 Jie Zhang Polyvinyl alcohol-containing compositions and methods for dermal delivery of drugs
US8907153B2 (en) 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
EP1634583A1 (en) 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
US20070082039A1 (en) 2004-10-18 2007-04-12 Jones Gerald S Jr Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
CN101217874B (zh) 2005-04-12 2012-06-06 优尼麦德药物股份有限公司 治疗或预防骨退化或骨质疏松症的方法
EP1868590A4 (en) 2005-04-13 2012-08-29 Unimed Pharmaceuticals Inc PROCESS FOR INCREASING TESTOSTERONE AND CORRESPONDING STEROID CONCENTRATIONS IN WOMEN
US8241664B2 (en) 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
ZA200711040B (en) 2005-06-03 2009-04-29 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
US20070065494A1 (en) 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
SI1937276T1 (sl) * 2005-10-12 2013-04-30 Unimed Pharmaceuticals, Llc C/O Abbott Laboratoires 100 Abbott Park Road Izboljšani testosteronski gel in postopek uporabe
US20070254036A1 (en) 2006-04-13 2007-11-01 Besins Healthcare Sa Treatment of menopause associated symptoms
US20080220068A1 (en) 2006-07-31 2008-09-11 Laboratories Besins International Treatment and prevention of excessive scarring
JP4148988B2 (ja) 2006-09-11 2008-09-10 積水化学工業株式会社 貼付剤
US20080261937A1 (en) 2007-03-23 2008-10-23 Dudley Robert E Pharmaceutical compositions and method for treating pediatric hypogonadism

Also Published As

Publication number Publication date
BRPI0617294B1 (pt) 2020-12-01
ZA200803087B (en) 2009-11-25
LT2450041T (lt) 2018-12-27
NO344564B1 (no) 2020-02-03
IL190522A0 (en) 2008-11-03
UA87627C2 (ru) 2009-07-27
RS52671B (en) 2013-06-28
HK1117417A1 (en) 2009-01-16
US20160228355A1 (en) 2016-08-11
AU2006299833A1 (en) 2007-04-19
TR201815853T4 (tr) 2018-11-21
US20110269729A1 (en) 2011-11-03
US8754070B2 (en) 2014-06-17
US8741881B2 (en) 2014-06-03
CA2624788C (en) 2011-04-19
AU2006299833B2 (en) 2012-04-12
US20130203720A1 (en) 2013-08-08
TNSN08167A1 (fr) 2009-10-30
US8466138B2 (en) 2013-06-18
EP3456329A1 (en) 2019-03-20
KR101342357B1 (ko) 2013-12-20
US8729057B2 (en) 2014-05-20
EP2450041A3 (en) 2012-08-01
BRPI0617294B8 (pt) 2021-05-25
EP2450041B1 (en) 2018-09-26
NO20082170L (no) 2008-05-09
JP5584415B2 (ja) 2014-09-03
US20070237822A1 (en) 2007-10-11
EP2450041A2 (en) 2012-05-09
PT1937276E (pt) 2013-02-21
IL190522A (en) 2015-04-30
CA2624788A1 (en) 2007-04-19
US8759329B2 (en) 2014-06-24
NO346660B1 (no) 2022-11-21
ECSP088363A (es) 2008-10-31
US20120028948A1 (en) 2012-02-02
US20120028946A1 (en) 2012-02-02
US8466136B2 (en) 2013-06-18
US20140329788A1 (en) 2014-11-06
NO20200014A1 (no) 2008-05-09
ES2399763T3 (es) 2013-04-03
WO2007044976A3 (en) 2007-09-07
SI1937276T1 (sl) 2013-04-30
PL2450041T3 (pl) 2019-02-28
KR20080068654A (ko) 2008-07-23
US20130210789A1 (en) 2013-08-15
GEP20125432B (en) 2012-03-26
JP2009511602A (ja) 2009-03-19
MA29941B1 (fr) 2008-11-03
PT2450041T (pt) 2018-11-16
NZ567056A (en) 2012-02-24
CN101287470B (zh) 2012-10-17
SI2450041T1 (sl) 2019-02-28
US20110306583A1 (en) 2011-12-15
EP1937276A2 (en) 2008-07-02
US8466137B2 (en) 2013-06-18
US20130210790A1 (en) 2013-08-15
CY1120904T1 (el) 2019-12-11
BRPI0617294A2 (pt) 2011-07-19
HRP20130071T1 (hr) 2013-03-31
EP1937276B1 (en) 2012-11-21
US20130210791A1 (en) 2013-08-15
CN101287470A (zh) 2008-10-15
US8486925B2 (en) 2013-07-16
ES2693745T3 (es) 2018-12-13
WO2007044976A2 (en) 2007-04-19
EA012754B1 (ru) 2009-12-30
DK2450041T3 (da) 2018-11-19
PL1937276T3 (pl) 2013-07-31
JP2013064028A (ja) 2013-04-11
EA200801049A1 (ru) 2008-08-29
JP5728508B2 (ja) 2015-06-03

Similar Documents

Publication Publication Date Title
DK1937276T3 (da) Forbedret testosterongel og fremgangsmåde til anvendelse deraf
DK1954140T3 (da) Glycerollevulinatketaler og deres anvendelse
DK1924577T3 (da) Substituerede benzimidazoler og fremgangsmåder til fremstilling
DK1894567T3 (da) Ledsagende farmaceutiske midler og anvendelse deraf
DK1934179T3 (da) Fremgangsmåder og mellemprodukter
DK2147315T3 (da) Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
DK1844155T3 (da) Sekvensspecifikke serinrekombinaser og fremgangsmåder til anvendelse deraf
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK1969391T3 (da) Tyndfilm emitter-absorber indretning og fremgangsmåde
DK2079485T3 (da) Phenylpropionamidforbindelser og anvendelsen deraf
DK1969846T3 (da) Systemer og fremgangsmåder til at administrere indhold
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK1919514T3 (da) Polynucleotider kodende for isoprenoid-modificerende enzymer og fremgangsmåder til anvendelse deraf
DK3366283T3 (da) Direkte sammenpresningsformulering og fremgangsmåde
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK1965763T3 (da) Stabile enzympræparater og fremgangsmåder til anvendelse heraf
DK2038275T3 (da) Ny pyridazinforbindelse og anvendelse heraf
DK1948695T3 (da) Immunogene sammensætninger og fremgangsmåder til andvendelse
DK1896571T3 (da) Materialer og fremgangsmåder, der vedrører cellebaserede behandlinger
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK1858488T4 (da) Tigecyclinsammensætninger og fremgangsmåder til fremstilling deraf
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK1991584T3 (da) Antistoffer mod human IL-22 og anvendelser deraf
NO20054709L (no) Sammenfoyningssystem og anvendelse av dette
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf